Endometriosis
What do patients say?
What do physicians say?
Our Innovative Technology
The recent marketing launch of Elagolix®, oral hormone therapy for endometriosis, has re-invigorated the conversation and drawn the attention of global community towards an unmet need for a simple diagnostic and non-hormonal treatment for endometriosis. Elagolix® has a forecast of over $1.15B in sales by 2022.
SYNG believes that our simple blood-test based diagnostic and non-hormone therapy will benefit from this positive market environment and defined regulatory pathway and, as SP012 may have disease-modifying capabilities in comparison to hormonal options, gaining the potential to achieve significant commercial success.
FOR PARTNERSHIP AND INVESTMENT OPPORTUNITIES
Market Play
The recent marketing launch of Elagolix®, an oral hormone therapy for endometriosis, has re-invigorated the conversation and drawn the attention of global community towards an unmet need of a simple diagnostic and non-hormonal therapy for endometriosis. Elagolix® has a forecast of over $1.15B in sales by 2022.
SYNG believes that our simple blood-test based diagnostic and non-hormone therapy will benefit from this positive market environment and defined regulatory pathway and, as SP012 may have disease-modifying capabilities in comparison to hormonal options, gaining the potential to achieve significant commercial success.
FOR PARTNERSHIP AND INVESTMENT OPPORTUNITIES